MEI Pharma winds down cancer drug program outside Japan, shares slip
05/12/2022 22:59
** Shares of cancer drug developer MEI Pharma Inc MEIP.O
fall 35.5% to $0.26 after market
** Company and partner Kyowa Kirin 4151.T discontinue
development of cancer drug zandelisib outside of Japan
urn:newsml:reuters.com:*:nBw32gQr9a
** MEIP announces plans to start a staggered workforce cut
of about 30% in connection with winding down of the cancer drug
program outside Japan urn:newsml:reuters.com:*:nBw8xZWZFa
** Kyowa Kirin to continue drug trials, explore potential
for submission to Japanese health authorities
** As of last close, MEI Pharma shares down 85.4% YTD
(Reporting by Nandhini Srinivasan in Bengaluru)
((nandhini.srinivasan@thomsonreuters.com))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations